Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)

Recruiting now · Phase 4

Conditions studied: Sickle Cell Anemia (HbSS), Sickle-β0-thalassemia (HbSβ0)

In brief

The main reason for this research study is to learn more about hydroxyurea and the treatment of sickle cell anemia (SCA). Hydroxyurea is a medication that has been studied for many years and has been shown to provide benefits for people with SCA. In this research study, the investigators hope to learn more about how to improve the dosing and monitoring of hydroxyurea and learn more about the long-term effects of hydroxyurea over time. Hydroxyurea is usually dosed based only on your weight. Our study will use a new way to select a starting dose that is based on how each patient absorbs hydroxyurea.

Key facts

Study ID

NCT07177300

Run by

Children's Hospital Medical Center, Cincinnati

People needed

50

Starts

2024-12-19

Expected to finish

2028-12-01

Last updated by the study team

2025-09-16

Who can join

Age: 1 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of sickle cell anemia (HbSS) or sickle-β0-thalassemia (HbSβ0)
• Age 6 months at the time of enrollment
• Clinical decision by patient, family, and healthcare provider to initiate hydroxyurea therapy

You may not qualify if…

• Current treatment with regularly scheduled blood transfusions
• Sickle-hemoglobin C disease (HbSC), sickle-β+-thalassemia (HbSβ+)

Where it is running

• Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.